nodes	percent_of_prediction	percent_of_DWPC	metapath
Ibandronate—Risedronate—PTGS2—colon cancer	0.00926	1	CrCbGaD
Ibandronate—FDPS—smooth muscle tissue—colon cancer	0.00805	0.166	CbGeAlD
Ibandronate—FDPS—renal system—colon cancer	0.00775	0.16	CbGeAlD
Ibandronate—FDPS—lymphoid tissue—colon cancer	0.00644	0.133	CbGeAlD
Ibandronate—FDPS—digestive system—colon cancer	0.00636	0.131	CbGeAlD
Ibandronate—FDPS—bone marrow—colon cancer	0.00586	0.121	CbGeAlD
Ibandronate—FDPS—vagina—colon cancer	0.00562	0.116	CbGeAlD
Ibandronate—FDPS—liver—colon cancer	0.00474	0.0978	CbGeAlD
Ibandronate—FDPS—lymph node—colon cancer	0.00363	0.075	CbGeAlD
Ibandronate—Mental disorder—Vincristine—colon cancer	0.00259	0.00275	CcSEcCtD
Ibandronate—Chills—Irinotecan—colon cancer	0.00259	0.00275	CcSEcCtD
Ibandronate—Ecchymosis—Methotrexate—colon cancer	0.00259	0.00275	CcSEcCtD
Ibandronate—Bladder pain—Methotrexate—colon cancer	0.00259	0.00275	CcSEcCtD
Ibandronate—Mouth ulceration—Methotrexate—colon cancer	0.00259	0.00275	CcSEcCtD
Ibandronate—Alopecia—Irinotecan—colon cancer	0.00255	0.0027	CcSEcCtD
Ibandronate—Abdominal pain upper—Capecitabine—colon cancer	0.00255	0.0027	CcSEcCtD
Ibandronate—Pulmonary oedema—Methotrexate—colon cancer	0.00255	0.0027	CcSEcCtD
Ibandronate—Breast disorder—Capecitabine—colon cancer	0.00252	0.00268	CcSEcCtD
Ibandronate—Nasopharyngitis—Capecitabine—colon cancer	0.00249	0.00265	CcSEcCtD
Ibandronate—Back pain—Vincristine—colon cancer	0.00249	0.00265	CcSEcCtD
Ibandronate—Flatulence—Irinotecan—colon cancer	0.00247	0.00262	CcSEcCtD
Ibandronate—Gastritis—Capecitabine—colon cancer	0.00247	0.00262	CcSEcCtD
Ibandronate—Alopecia—Fluorouracil—colon cancer	0.00244	0.00259	CcSEcCtD
Ibandronate—Back pain—Irinotecan—colon cancer	0.00243	0.00258	CcSEcCtD
Ibandronate—Muscle spasms—Irinotecan—colon cancer	0.00241	0.00256	CcSEcCtD
Ibandronate—Influenza—Capecitabine—colon cancer	0.00241	0.00256	CcSEcCtD
Ibandronate—Asthma—Capecitabine—colon cancer	0.00241	0.00256	CcSEcCtD
Ibandronate—Dysphagia—Capecitabine—colon cancer	0.00241	0.00256	CcSEcCtD
Ibandronate—Erythema—Fluorouracil—colon cancer	0.0024	0.00255	CcSEcCtD
Ibandronate—Anaemia—Vincristine—colon cancer	0.00238	0.00253	CcSEcCtD
Ibandronate—Bronchospasm—Capecitabine—colon cancer	0.00237	0.00252	CcSEcCtD
Ibandronate—Ill-defined disorder—Irinotecan—colon cancer	0.00233	0.00247	CcSEcCtD
Ibandronate—Anaemia—Irinotecan—colon cancer	0.00232	0.00246	CcSEcCtD
Ibandronate—Bronchitis—Capecitabine—colon cancer	0.00232	0.00246	CcSEcCtD
Ibandronate—Vertigo—Vincristine—colon cancer	0.00232	0.00246	CcSEcCtD
Ibandronate—Abdominal discomfort—Capecitabine—colon cancer	0.00231	0.00245	CcSEcCtD
Ibandronate—Malaise—Irinotecan—colon cancer	0.00226	0.0024	CcSEcCtD
Ibandronate—Vertigo—Irinotecan—colon cancer	0.00226	0.00239	CcSEcCtD
Ibandronate—Renal failure acute—Methotrexate—colon cancer	0.00225	0.00239	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Capecitabine—colon cancer	0.00224	0.00238	CcSEcCtD
Ibandronate—Hypertension—Vincristine—colon cancer	0.00223	0.00236	CcSEcCtD
Ibandronate—Anaemia—Fluorouracil—colon cancer	0.00222	0.00236	CcSEcCtD
Ibandronate—Myalgia—Vincristine—colon cancer	0.00219	0.00233	CcSEcCtD
Ibandronate—Weight decreased—Capecitabine—colon cancer	0.00218	0.00231	CcSEcCtD
Ibandronate—Hypertension—Irinotecan—colon cancer	0.00217	0.0023	CcSEcCtD
Ibandronate—Pneumonia—Capecitabine—colon cancer	0.00216	0.00229	CcSEcCtD
Ibandronate—Infestation NOS—Capecitabine—colon cancer	0.00215	0.00228	CcSEcCtD
Ibandronate—Infestation—Capecitabine—colon cancer	0.00215	0.00228	CcSEcCtD
Ibandronate—Depression—Capecitabine—colon cancer	0.00214	0.00227	CcSEcCtD
Ibandronate—Renal failure—Capecitabine—colon cancer	0.00211	0.00224	CcSEcCtD
Ibandronate—Discomfort—Irinotecan—colon cancer	0.00211	0.00224	CcSEcCtD
Ibandronate—Anaphylactic shock—Vincristine—colon cancer	0.0021	0.00223	CcSEcCtD
Ibandronate—Stomatitis—Capecitabine—colon cancer	0.0021	0.00222	CcSEcCtD
Ibandronate—Infection—Vincristine—colon cancer	0.00209	0.00222	CcSEcCtD
Ibandronate—Urinary tract infection—Capecitabine—colon cancer	0.00209	0.00222	CcSEcCtD
Ibandronate—Osteoarthritis—Methotrexate—colon cancer	0.00208	0.0022	CcSEcCtD
Ibandronate—Nervous system disorder—Vincristine—colon cancer	0.00206	0.00219	CcSEcCtD
Ibandronate—Anaphylactic shock—Irinotecan—colon cancer	0.00205	0.00217	CcSEcCtD
Ibandronate—Myalgia—Fluorouracil—colon cancer	0.00205	0.00217	CcSEcCtD
Ibandronate—Chest pain—Fluorouracil—colon cancer	0.00205	0.00217	CcSEcCtD
Ibandronate—Infection—Irinotecan—colon cancer	0.00204	0.00216	CcSEcCtD
Ibandronate—Hyperhidrosis—Vincristine—colon cancer	0.00203	0.00216	CcSEcCtD
Ibandronate—Hepatobiliary disease—Capecitabine—colon cancer	0.00203	0.00216	CcSEcCtD
Ibandronate—Discomfort—Fluorouracil—colon cancer	0.00202	0.00215	CcSEcCtD
Ibandronate—Shock—Irinotecan—colon cancer	0.00202	0.00214	CcSEcCtD
Ibandronate—Nervous system disorder—Irinotecan—colon cancer	0.00201	0.00213	CcSEcCtD
Ibandronate—Hyperhidrosis—Irinotecan—colon cancer	0.00198	0.0021	CcSEcCtD
Ibandronate—Anaphylactic shock—Fluorouracil—colon cancer	0.00196	0.00208	CcSEcCtD
Ibandronate—Infection—Fluorouracil—colon cancer	0.00195	0.00207	CcSEcCtD
Ibandronate—Haemoglobin—Capecitabine—colon cancer	0.00194	0.00206	CcSEcCtD
Ibandronate—Haemorrhage—Capecitabine—colon cancer	0.00193	0.00205	CcSEcCtD
Ibandronate—Nervous system disorder—Fluorouracil—colon cancer	0.00192	0.00204	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Vincristine—colon cancer	0.00192	0.00203	CcSEcCtD
Ibandronate—Pharyngitis—Capecitabine—colon cancer	0.00192	0.00203	CcSEcCtD
Ibandronate—Urinary tract disorder—Capecitabine—colon cancer	0.00191	0.00202	CcSEcCtD
Ibandronate—Insomnia—Vincristine—colon cancer	0.0019	0.00202	CcSEcCtD
Ibandronate—Oedema peripheral—Capecitabine—colon cancer	0.0019	0.00202	CcSEcCtD
Ibandronate—Connective tissue disorder—Capecitabine—colon cancer	0.0019	0.00201	CcSEcCtD
Ibandronate—Urethral disorder—Capecitabine—colon cancer	0.00189	0.00201	CcSEcCtD
Ibandronate—Paraesthesia—Vincristine—colon cancer	0.00189	0.002	CcSEcCtD
Ibandronate—Breast disorder—Methotrexate—colon cancer	0.00188	0.00199	CcSEcCtD
Ibandronate—Insomnia—Irinotecan—colon cancer	0.00185	0.00197	CcSEcCtD
Ibandronate—Paraesthesia—Irinotecan—colon cancer	0.00184	0.00195	CcSEcCtD
Ibandronate—Decreased appetite—Vincristine—colon cancer	0.00183	0.00194	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Vincristine—colon cancer	0.00182	0.00193	CcSEcCtD
Ibandronate—Fatigue—Vincristine—colon cancer	0.00181	0.00192	CcSEcCtD
Ibandronate—Eye disorder—Capecitabine—colon cancer	0.0018	0.00191	CcSEcCtD
Ibandronate—Dyspepsia—Irinotecan—colon cancer	0.0018	0.00191	CcSEcCtD
Ibandronate—Constipation—Vincristine—colon cancer	0.0018	0.00191	CcSEcCtD
Ibandronate—Pain—Vincristine—colon cancer	0.0018	0.00191	CcSEcCtD
Ibandronate—Asthma—Methotrexate—colon cancer	0.00179	0.0019	CcSEcCtD
Ibandronate—Cardiac disorder—Capecitabine—colon cancer	0.00179	0.0019	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00179	0.0019	CcSEcCtD
Ibandronate—Decreased appetite—Irinotecan—colon cancer	0.00178	0.00189	CcSEcCtD
Ibandronate—Insomnia—Fluorouracil—colon cancer	0.00177	0.00188	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Irinotecan—colon cancer	0.00177	0.00188	CcSEcCtD
Ibandronate—Fatigue—Irinotecan—colon cancer	0.00177	0.00187	CcSEcCtD
Ibandronate—Paraesthesia—Fluorouracil—colon cancer	0.00176	0.00187	CcSEcCtD
Ibandronate—Pain—Irinotecan—colon cancer	0.00175	0.00186	CcSEcCtD
Ibandronate—Constipation—Irinotecan—colon cancer	0.00175	0.00186	CcSEcCtD
Ibandronate—Angiopathy—Capecitabine—colon cancer	0.00175	0.00186	CcSEcCtD
Ibandronate—Immune system disorder—Capecitabine—colon cancer	0.00174	0.00185	CcSEcCtD
Ibandronate—Mediastinal disorder—Capecitabine—colon cancer	0.00174	0.00185	CcSEcCtD
Ibandronate—Chills—Capecitabine—colon cancer	0.00173	0.00184	CcSEcCtD
Ibandronate—Dyspepsia—Fluorouracil—colon cancer	0.00173	0.00183	CcSEcCtD
Ibandronate—Abdominal discomfort—Methotrexate—colon cancer	0.00172	0.00183	CcSEcCtD
Ibandronate—Gastrointestinal pain—Vincristine—colon cancer	0.00172	0.00183	CcSEcCtD
Ibandronate—Decreased appetite—Fluorouracil—colon cancer	0.00171	0.00181	CcSEcCtD
Ibandronate—Alopecia—Capecitabine—colon cancer	0.00171	0.00181	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00169	0.0018	CcSEcCtD
Ibandronate—Mental disorder—Capecitabine—colon cancer	0.00169	0.00179	CcSEcCtD
Ibandronate—Feeling abnormal—Irinotecan—colon cancer	0.00169	0.00179	CcSEcCtD
Ibandronate—Malnutrition—Capecitabine—colon cancer	0.00168	0.00178	CcSEcCtD
Ibandronate—Erythema—Capecitabine—colon cancer	0.00168	0.00178	CcSEcCtD
Ibandronate—Pain—Fluorouracil—colon cancer	0.00168	0.00178	CcSEcCtD
Ibandronate—Gastrointestinal pain—Irinotecan—colon cancer	0.00168	0.00178	CcSEcCtD
Ibandronate—Upper respiratory tract infection—Methotrexate—colon cancer	0.00167	0.00177	CcSEcCtD
Ibandronate—Abdominal pain—Vincristine—colon cancer	0.00166	0.00176	CcSEcCtD
Ibandronate—Body temperature increased—Vincristine—colon cancer	0.00166	0.00176	CcSEcCtD
Ibandronate—Flatulence—Capecitabine—colon cancer	0.00166	0.00176	CcSEcCtD
Ibandronate—Dysgeusia—Capecitabine—colon cancer	0.00165	0.00175	CcSEcCtD
Ibandronate—Back pain—Capecitabine—colon cancer	0.00163	0.00172	CcSEcCtD
Ibandronate—Abdominal pain—Irinotecan—colon cancer	0.00162	0.00172	CcSEcCtD
Ibandronate—Body temperature increased—Irinotecan—colon cancer	0.00162	0.00172	CcSEcCtD
Ibandronate—Feeling abnormal—Fluorouracil—colon cancer	0.00162	0.00172	CcSEcCtD
Ibandronate—Muscle spasms—Capecitabine—colon cancer	0.00162	0.00171	CcSEcCtD
Ibandronate—Pneumonia—Methotrexate—colon cancer	0.00161	0.00171	CcSEcCtD
Ibandronate—Infestation—Methotrexate—colon cancer	0.0016	0.0017	CcSEcCtD
Ibandronate—Infestation NOS—Methotrexate—colon cancer	0.0016	0.0017	CcSEcCtD
Ibandronate—Depression—Methotrexate—colon cancer	0.0016	0.00169	CcSEcCtD
Ibandronate—Renal failure—Methotrexate—colon cancer	0.00157	0.00167	CcSEcCtD
Ibandronate—Stomatitis—Methotrexate—colon cancer	0.00156	0.00166	CcSEcCtD
Ibandronate—Ill-defined disorder—Capecitabine—colon cancer	0.00156	0.00165	CcSEcCtD
Ibandronate—Urticaria—Fluorouracil—colon cancer	0.00156	0.00165	CcSEcCtD
Ibandronate—Anaemia—Capecitabine—colon cancer	0.00155	0.00165	CcSEcCtD
Ibandronate—Body temperature increased—Fluorouracil—colon cancer	0.00155	0.00165	CcSEcCtD
Ibandronate—Hypersensitivity—Vincristine—colon cancer	0.00155	0.00164	CcSEcCtD
Ibandronate—Sweating—Methotrexate—colon cancer	0.00153	0.00163	CcSEcCtD
Ibandronate—Malaise—Capecitabine—colon cancer	0.00152	0.00161	CcSEcCtD
Ibandronate—Hepatobiliary disease—Methotrexate—colon cancer	0.00151	0.00161	CcSEcCtD
Ibandronate—Vertigo—Capecitabine—colon cancer	0.00151	0.0016	CcSEcCtD
Ibandronate—Hypersensitivity—Irinotecan—colon cancer	0.00151	0.0016	CcSEcCtD
Ibandronate—Asthenia—Vincristine—colon cancer	0.00151	0.0016	CcSEcCtD
Ibandronate—Palpitations—Capecitabine—colon cancer	0.00148	0.00158	CcSEcCtD
Ibandronate—Asthenia—Irinotecan—colon cancer	0.00147	0.00156	CcSEcCtD
Ibandronate—Hypertension—Capecitabine—colon cancer	0.00145	0.00154	CcSEcCtD
Ibandronate—Hypersensitivity—Fluorouracil—colon cancer	0.00145	0.00153	CcSEcCtD
Ibandronate—Haemoglobin—Methotrexate—colon cancer	0.00144	0.00153	CcSEcCtD
Ibandronate—Diarrhoea—Vincristine—colon cancer	0.00144	0.00153	CcSEcCtD
Ibandronate—Haemorrhage—Methotrexate—colon cancer	0.00144	0.00152	CcSEcCtD
Ibandronate—Chest pain—Capecitabine—colon cancer	0.00143	0.00152	CcSEcCtD
Ibandronate—Myalgia—Capecitabine—colon cancer	0.00143	0.00152	CcSEcCtD
Ibandronate—Arthralgia—Capecitabine—colon cancer	0.00143	0.00152	CcSEcCtD
Ibandronate—Pharyngitis—Methotrexate—colon cancer	0.00143	0.00151	CcSEcCtD
Ibandronate—Anxiety—Capecitabine—colon cancer	0.00143	0.00151	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00142	0.00151	CcSEcCtD
Ibandronate—Urinary tract disorder—Methotrexate—colon cancer	0.00142	0.00151	CcSEcCtD
Ibandronate—Discomfort—Capecitabine—colon cancer	0.00141	0.0015	CcSEcCtD
Ibandronate—Urethral disorder—Methotrexate—colon cancer	0.00141	0.00149	CcSEcCtD
Ibandronate—Diarrhoea—Irinotecan—colon cancer	0.0014	0.00149	CcSEcCtD
Ibandronate—Dry mouth—Capecitabine—colon cancer	0.0014	0.00148	CcSEcCtD
Ibandronate—Dizziness—Vincristine—colon cancer	0.00139	0.00148	CcSEcCtD
Ibandronate—Pruritus—Fluorouracil—colon cancer	0.00139	0.00147	CcSEcCtD
Ibandronate—Infection—Capecitabine—colon cancer	0.00136	0.00145	CcSEcCtD
Ibandronate—Dizziness—Irinotecan—colon cancer	0.00135	0.00144	CcSEcCtD
Ibandronate—Shock—Capecitabine—colon cancer	0.00135	0.00143	CcSEcCtD
Ibandronate—Nervous system disorder—Capecitabine—colon cancer	0.00134	0.00143	CcSEcCtD
Ibandronate—Eye disorder—Methotrexate—colon cancer	0.00134	0.00142	CcSEcCtD
Ibandronate—Diarrhoea—Fluorouracil—colon cancer	0.00134	0.00142	CcSEcCtD
Ibandronate—Vomiting—Vincristine—colon cancer	0.00134	0.00142	CcSEcCtD
Ibandronate—Cardiac disorder—Methotrexate—colon cancer	0.00133	0.00142	CcSEcCtD
Ibandronate—Skin disorder—Capecitabine—colon cancer	0.00133	0.00141	CcSEcCtD
Ibandronate—Rash—Vincristine—colon cancer	0.00133	0.00141	CcSEcCtD
Ibandronate—Hyperhidrosis—Capecitabine—colon cancer	0.00133	0.00141	CcSEcCtD
Ibandronate—Dermatitis—Vincristine—colon cancer	0.00133	0.00141	CcSEcCtD
Ibandronate—Headache—Vincristine—colon cancer	0.00132	0.0014	CcSEcCtD
Ibandronate—Angiopathy—Methotrexate—colon cancer	0.0013	0.00138	CcSEcCtD
Ibandronate—Vomiting—Irinotecan—colon cancer	0.0013	0.00138	CcSEcCtD
Ibandronate—Immune system disorder—Methotrexate—colon cancer	0.0013	0.00138	CcSEcCtD
Ibandronate—Dizziness—Fluorouracil—colon cancer	0.0013	0.00138	CcSEcCtD
Ibandronate—Mediastinal disorder—Methotrexate—colon cancer	0.00129	0.00137	CcSEcCtD
Ibandronate—Rash—Irinotecan—colon cancer	0.00129	0.00137	CcSEcCtD
Ibandronate—Dermatitis—Irinotecan—colon cancer	0.00129	0.00137	CcSEcCtD
Ibandronate—Chills—Methotrexate—colon cancer	0.00129	0.00137	CcSEcCtD
Ibandronate—Headache—Irinotecan—colon cancer	0.00128	0.00136	CcSEcCtD
Ibandronate—Alopecia—Methotrexate—colon cancer	0.00127	0.00135	CcSEcCtD
Ibandronate—Mental disorder—Methotrexate—colon cancer	0.00126	0.00134	CcSEcCtD
Ibandronate—Erythema—Methotrexate—colon cancer	0.00125	0.00133	CcSEcCtD
Ibandronate—Malnutrition—Methotrexate—colon cancer	0.00125	0.00133	CcSEcCtD
Ibandronate—Nausea—Vincristine—colon cancer	0.00125	0.00133	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00125	0.00133	CcSEcCtD
Ibandronate—Vomiting—Fluorouracil—colon cancer	0.00125	0.00132	CcSEcCtD
Ibandronate—Insomnia—Capecitabine—colon cancer	0.00124	0.00132	CcSEcCtD
Ibandronate—Rash—Fluorouracil—colon cancer	0.00124	0.00131	CcSEcCtD
Ibandronate—Dermatitis—Fluorouracil—colon cancer	0.00124	0.00131	CcSEcCtD
Ibandronate—Paraesthesia—Capecitabine—colon cancer	0.00123	0.00131	CcSEcCtD
Ibandronate—Headache—Fluorouracil—colon cancer	0.00123	0.0013	CcSEcCtD
Ibandronate—Dysgeusia—Methotrexate—colon cancer	0.00122	0.0013	CcSEcCtD
Ibandronate—Nausea—Irinotecan—colon cancer	0.00122	0.00129	CcSEcCtD
Ibandronate—Back pain—Methotrexate—colon cancer	0.00121	0.00128	CcSEcCtD
Ibandronate—Dyspepsia—Capecitabine—colon cancer	0.00121	0.00128	CcSEcCtD
Ibandronate—Decreased appetite—Capecitabine—colon cancer	0.00119	0.00126	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Capecitabine—colon cancer	0.00118	0.00126	CcSEcCtD
Ibandronate—Fatigue—Capecitabine—colon cancer	0.00118	0.00125	CcSEcCtD
Ibandronate—Pain—Capecitabine—colon cancer	0.00117	0.00124	CcSEcCtD
Ibandronate—Constipation—Capecitabine—colon cancer	0.00117	0.00124	CcSEcCtD
Ibandronate—Nausea—Fluorouracil—colon cancer	0.00117	0.00124	CcSEcCtD
Ibandronate—Ill-defined disorder—Methotrexate—colon cancer	0.00116	0.00123	CcSEcCtD
Ibandronate—Anaemia—Methotrexate—colon cancer	0.00116	0.00123	CcSEcCtD
Ibandronate—Feeling abnormal—Capecitabine—colon cancer	0.00113	0.0012	CcSEcCtD
Ibandronate—Malaise—Methotrexate—colon cancer	0.00113	0.0012	CcSEcCtD
Ibandronate—Vertigo—Methotrexate—colon cancer	0.00112	0.00119	CcSEcCtD
Ibandronate—Gastrointestinal pain—Capecitabine—colon cancer	0.00112	0.00119	CcSEcCtD
Ibandronate—Urticaria—Capecitabine—colon cancer	0.00109	0.00116	CcSEcCtD
Ibandronate—Abdominal pain—Capecitabine—colon cancer	0.00108	0.00115	CcSEcCtD
Ibandronate—Body temperature increased—Capecitabine—colon cancer	0.00108	0.00115	CcSEcCtD
Ibandronate—Arthralgia—Methotrexate—colon cancer	0.00106	0.00113	CcSEcCtD
Ibandronate—Myalgia—Methotrexate—colon cancer	0.00106	0.00113	CcSEcCtD
Ibandronate—Chest pain—Methotrexate—colon cancer	0.00106	0.00113	CcSEcCtD
Ibandronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00106	0.00112	CcSEcCtD
Ibandronate—Discomfort—Methotrexate—colon cancer	0.00105	0.00112	CcSEcCtD
Ibandronate—Anaphylactic shock—Methotrexate—colon cancer	0.00102	0.00108	CcSEcCtD
Ibandronate—Infection—Methotrexate—colon cancer	0.00101	0.00108	CcSEcCtD
Ibandronate—Hypersensitivity—Capecitabine—colon cancer	0.00101	0.00107	CcSEcCtD
Ibandronate—Nervous system disorder—Methotrexate—colon cancer	0.001	0.00106	CcSEcCtD
Ibandronate—Skin disorder—Methotrexate—colon cancer	0.000991	0.00105	CcSEcCtD
Ibandronate—Hyperhidrosis—Methotrexate—colon cancer	0.000987	0.00105	CcSEcCtD
Ibandronate—Asthenia—Capecitabine—colon cancer	0.000984	0.00104	CcSEcCtD
Ibandronate—Pruritus—Capecitabine—colon cancer	0.00097	0.00103	CcSEcCtD
Ibandronate—Diarrhoea—Capecitabine—colon cancer	0.000938	0.000996	CcSEcCtD
Ibandronate—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00093	0.000987	CcSEcCtD
Ibandronate—Insomnia—Methotrexate—colon cancer	0.000923	0.00098	CcSEcCtD
Ibandronate—Paraesthesia—Methotrexate—colon cancer	0.000917	0.000973	CcSEcCtD
Ibandronate—Dizziness—Capecitabine—colon cancer	0.000907	0.000962	CcSEcCtD
Ibandronate—Dyspepsia—Methotrexate—colon cancer	0.000898	0.000954	CcSEcCtD
Ibandronate—Decreased appetite—Methotrexate—colon cancer	0.000887	0.000942	CcSEcCtD
Ibandronate—Gastrointestinal disorder—Methotrexate—colon cancer	0.000881	0.000935	CcSEcCtD
Ibandronate—Fatigue—Methotrexate—colon cancer	0.00088	0.000934	CcSEcCtD
Ibandronate—Pain—Methotrexate—colon cancer	0.000873	0.000926	CcSEcCtD
Ibandronate—Vomiting—Capecitabine—colon cancer	0.000872	0.000925	CcSEcCtD
Ibandronate—Rash—Capecitabine—colon cancer	0.000865	0.000917	CcSEcCtD
Ibandronate—Dermatitis—Capecitabine—colon cancer	0.000864	0.000917	CcSEcCtD
Ibandronate—Headache—Capecitabine—colon cancer	0.000859	0.000912	CcSEcCtD
Ibandronate—Feeling abnormal—Methotrexate—colon cancer	0.000841	0.000893	CcSEcCtD
Ibandronate—Gastrointestinal pain—Methotrexate—colon cancer	0.000835	0.000886	CcSEcCtD
Ibandronate—Nausea—Capecitabine—colon cancer	0.000814	0.000864	CcSEcCtD
Ibandronate—Urticaria—Methotrexate—colon cancer	0.000811	0.000861	CcSEcCtD
Ibandronate—Body temperature increased—Methotrexate—colon cancer	0.000807	0.000856	CcSEcCtD
Ibandronate—Abdominal pain—Methotrexate—colon cancer	0.000807	0.000856	CcSEcCtD
Ibandronate—Hypersensitivity—Methotrexate—colon cancer	0.000752	0.000798	CcSEcCtD
Ibandronate—Asthenia—Methotrexate—colon cancer	0.000732	0.000777	CcSEcCtD
Ibandronate—Pruritus—Methotrexate—colon cancer	0.000722	0.000766	CcSEcCtD
Ibandronate—Diarrhoea—Methotrexate—colon cancer	0.000698	0.000741	CcSEcCtD
Ibandronate—Dizziness—Methotrexate—colon cancer	0.000675	0.000716	CcSEcCtD
Ibandronate—Vomiting—Methotrexate—colon cancer	0.000649	0.000689	CcSEcCtD
Ibandronate—Rash—Methotrexate—colon cancer	0.000644	0.000683	CcSEcCtD
Ibandronate—Dermatitis—Methotrexate—colon cancer	0.000643	0.000682	CcSEcCtD
Ibandronate—Headache—Methotrexate—colon cancer	0.000639	0.000679	CcSEcCtD
Ibandronate—Nausea—Methotrexate—colon cancer	0.000606	0.000643	CcSEcCtD
